Navigation Links
Tarix Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Study of TXA127 Following Autologous Peripheral Blood Stem Cell Transplant
Date:2/23/2011

usion of CD34+ cells. The study is expected to enroll a total of 74 patients at eight leading U.S. medical centers. For more information, please visit http://clinicaltrials.gov/ct2/show/NCT01121120?term=tarix&rank=2.

TXA127 will also be evaluated in two clinical trials in cord blood transplantation. One conducted at M D Anderson will involve adult patients, while the other at Duke University, will enroll pediatric patients.

About Tarix Pharmaceuticals

Tarix Pharmaceuticals is a clinical stage biopharmaceutical company developing peptide drugs to address significant unmet medical needs. The Company's lead product, TXA127, is a pharmaceutical formulation of the naturally occurring peptide, Angiotensin (1-7). TXA127 is currently in a Phase II clinical trial for the treatment and prevention of thrombocytopenia (reduced platelet count) associated with cancer chemotherapy, and a Phase II trial for peripheral blood stem cell engraftment. Tarix is preparing additional clinical trials with TXA127 in acute respiratory distress syndrome (ARDS), cord blood stem cell engraftment, and myelodysplastic syndrome (MDS). TXA127 is also being developed, under grants from the US government, as a treatment for radiation exposure.

Tarix's second product, PanCyte, is a synthetic, long-acting analogue of Angiotensin (1-7). PanCyte is in pre-clinical development focused on chemotherapy-induced thrombocytopenia and neutropenia, as well as combination treatment with low dose erythropoietin in chemotherapy-induced anemia.


'/>"/>
SOURCE Tarix Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Components of Extraneous Virus Detected in Rotarix Vaccine; No Known Safety Risk
2. Paul Capital Healthcare Purchases Additional Royalty Interest in GlaxoSmithKlines Rotarix(R)
3. New Data Published in The Lancet Show GSKs ROTARIX(R) Offers Protection Against the Most Common Circulating Rotavirus Types
4. New Data Show That GlaxoSmithKlines Rotarix(R) Could Be Given With Other Routine Infant Vaccines in the U.S.
5. Idenix Pharmaceuticals to Present at an Upcoming Investor Conference
6. Onyx Pharmaceuticals Reports Full Year and Fourth Quarter 2010 Financial Results
7. Avanir Pharmaceuticals to Present at Three Conferences in March
8. MAP Pharmaceuticals to Present at Upcoming Investor Conferences
9. Isis Pharmaceuticals Reports That Its Selective CRP Inhibitor Demonstrated Activity in a Phase 1 Study
10. Isis Pharmaceuticals to Present at the 2011 Citi Global Healthcare Conference
11. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Pa. , July 31, 2015 ... fully integrated specialty pharmaceutical company focused on developing, ... the closing of its previously announced underwritten public ... at a public offering price of $11.25 per ... offering included 1,000,000 shares issued upon the exercise ...
(Date:7/31/2015)... According to a new market ... Analyzers (BIA), Dual-Energy X-ray Absorptiometry (DEXA), Skinfold Calipers, Air ... & Forecast to 2019", published by MarketsandMarkets, the global ... 2014 and is estimated to grow to $1,425.7 Million ... 2014 to 2019. Browse 41 market ...
(Date:7/30/2015)... July 30, 2015  ResMed (NYSE: ... a definitive agreement to acquire Curative Medical, ... and sleep-disordered breathing medical devices and accessories. ... in China, combined with ResMed,s global leadership in sleep and respiratory ... China suffering from sleep-disordered ...
Breaking Medicine Technology:Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 2Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 3Egalet Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to Purchase Additional Shares 4Body Composition Analyzers Market Worth $1,425.7 Million by 2019 2Body Composition Analyzers Market Worth $1,425.7 Million by 2019 3Body Composition Analyzers Market Worth $1,425.7 Million by 2019 4ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
... Cardiothoracic Surgeons to Lead Pivotal TrialANN ARBOR, Mich., March ... has appointed David Seth Feldman, MD/PhD, FACC, FAHA to ... the United States, studying the new, third generation DuraHeart(TM) ... Dr. Francis Pagani, Director of the Heart Transplant and ...
... - Conference Call Today at 5:00 p.m. Eastern Time ... Pharmaceuticals, Inc. (Nasdaq: PARD ), a biopharmaceutical ... the fourth quarter and year ended December 31, 2008, ... of 2008, we made significant progress toward our goal ...
Cached Medicine Technology:David Feldman, M.D. Appointed Co-Principal Investigator of DuraHeart(TM) Left Ventricular Assist System U.S. Clinical Trial 2David Feldman, M.D. Appointed Co-Principal Investigator of DuraHeart(TM) Left Ventricular Assist System U.S. Clinical Trial 3Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 2Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 3Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 4Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 5Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 6Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 7Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 8Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update 9
(Date:8/1/2015)... ... August 01, 2015 , ... On March 19, 2015 Phil Valentine – the Executive Director of ... Appalachian Trail by stepping off Springer Mountain and heading north. Since that day, Phil ... reached Connecticut and was greeted by friends and family. He visited CCAR and left ...
(Date:7/31/2015)... ... , ... Super Bowl 50 will emanate from Levi’s Stadium in Santa Clara, CA ... the Super Bowl. In the two weeks that separate the conference championships and the Super ... Super Bowl game will mark the 50th time it has been held and the festivities ...
(Date:7/31/2015)... Tenn. (PRWEB) , ... July 31, 2015 , ... The ... Robert Church Park in Downtown Memphis on October 3, 2015. The Ride to Fight ... focused on cancer research between Methodist Healthcare, The West Clinic and The University of ...
(Date:7/31/2015)... ... ... Coco Libre announced today that their flagship Organic Coconut Water will be ... Open of Surfing, July 25 through August 2 in Huntington Beach, California. Coco Libre, ... is a natural choice given the Open’s commitment to sustainable practices. , Designated ...
(Date:7/31/2015)... ... ... Well-known for its unique pastries and delicious confections, Pastry Palace, a popular ... life just a little bit sweeter for newlyweds. A family-owned business, the Pastry Palace ... , The bakery provides a full line of custom wedding cakes. Brides can select ...
Breaking Medicine News(10 mins):Health News:Connecticut Executive Hikes Appalachian Trail to Raise Awareness About Recovery. 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2
... (NYSE: TYC , BSX: TYC) announced today that ... quarterly dividend to 15,cents per share for the first ... 36% increase over the quarterly dividend of,approximately 11 cents ... the separation of Tyco into three public companies. The,15-cent ...
... ViroPharma Incorporated,(Nasdaq: VPHM ) today announced ... financial officer of ViroPharma, will present,at the Maxim ... ET on,Thursday, September 20, 2007. The conference is ... ViroPharma,s presentation will be webcast live for ...
... straight men equally prone to unprotected sex, research shows , , ... gay men can,t be explained by their number of sexual ... HIV infections diagnosed in the United States in 2005 were ... Seattle, noted. In addition, as many as one in five ...
... Institute have shown that several, rather than just ... brain tumors and other solid tumors, explaining why ... often yields disappointing results. , The laboratory finding ... combine three or more such targeted drugs for ...
... Sept. 13 Mayo Clinic,s,Multidisciplinary Simulation Center is ... the United States to be accredited by,the American ... positions,Mayo to offer and advance medical education that ... members, abilities to keep pace with,rapidly changing technologies. ...
... Minnesota Twins and at Interlachen Country Club ... and support for suicide prevention., MINNEAPOLIS, Sept. 13 ... Prevention Week,(September 9-15, 2007) this week with a special ... at the Hubert H. Humphrey Metrodome in,Minneapolis. SAVE is ...
Cached Medicine News:Health News:Tyco International Increases Quarterly Dividend 36 Percent to 15 Cents per Share; Initiates New $1 Billion Share Repurchase Program 2Health News:Number of Partners Doesn't Explain Gay HIV Rate 2Health News:Number of Partners Doesn't Explain Gay HIV Rate 3Health News:Study suggests brain tumors need treatment with multiple 'targeted' drugs 2Health News:Study suggests brain tumors need treatment with multiple 'targeted' drugs 3Health News:Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute 2Health News:Mayo Clinic Multidisciplinary Simulation Center Receives Distinction as an ACS-Accredited Education Institute 3Health News:SAVE Recognizes National Suicide Prevention Week 2
Microseal 'F' foil, seals plates for cold storage (or cycling >25l), disposable, pkg of 100...
Pkg qty: box of 2 bags pack of 25 (Pack = Zippered Bag)...
Transparent film for easy visual monitoring of samples...
... Biosystems has developed a comprehensive set ... using sequence detection systems (SDS) reagents ... and easy to follow. Many traditional ... and the thermal cycling protocol itself, ...
Medicine Products: